The identification of DSF, a clinically safe and inexpensive drug, as a FROUNT inhibitor that has synergistic antitumor effects when combined with immune-checkpoint therapy suggests that modulation of chemokine signaling by targeting FROUNT represents a promising and readily realizable strategy for macrophage-targeted cancer therapy. Here, NUP85 is linked to cancer.